Patents Assigned to Sylentis S.A.U.
-
Patent number: 9018183Abstract: The invention relates to methods and compositions for the treatment/and or prevention of eye conditions related to high levels of expression and/or activity of the vanilloid-1 receptor (TRPV).Type: GrantFiled: May 27, 2011Date of Patent: April 28, 2015Assignee: Sylentis S.A.U.Inventors: Marta Lopez-Fraga, Ana Isabel Jimenez, Tamara Martinez Valcarel
-
Patent number: 8951982Abstract: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof of an effective amount of one or more siNAs of the invention.Type: GrantFiled: January 18, 2013Date of Patent: February 10, 2015Assignee: Sylentis S.A.U.Inventors: Ana I. Jiménez, Ángela Sesto, Irene Gascón, José P. Román, Gonzalo González de Buitrago
-
Patent number: 8871729Abstract: Methods and compositions for the treatment of pathologic conditions of the central nervous system (CNS) by means of intranasal administration of a composition that modulates, by means of RNA interference, the expression and/or activity of genes involved in above-mentioned conditions.Type: GrantFiled: March 16, 2007Date of Patent: October 28, 2014Assignee: Sylentis, S.A.U.Inventors: Angela Sesto Yague, Eduardo Gomez-Acebo Gullon, Ma Concepción Jiménez Gomez, Ana Isabel Jiménez Antón
-
Patent number: 8703731Abstract: The invention relates to novel oligomer analogues and their use in oligonucleotide-based therapies. More specifically, the invention concerns oligonucleotides carrying lipid molecules and their use as potential inhibitors of gene expression.Type: GrantFiled: June 22, 2010Date of Patent: April 22, 2014Assignee: Sylentis S.A.U.Inventors: Ana Isabel Jimenez, Gema Panizo, Tamara Martinez, Anna Avino, Clara Caminal, Ramon Eritja, Santiago Grijalvo
-
Publication number: 20140018527Abstract: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof of an effective amount of one or more siNAs of the invention.Type: ApplicationFiled: January 18, 2013Publication date: January 16, 2014Applicant: Sylentis S.A.UInventors: Ana I. Jiménez, Ángela Sesto, Irene Gascón, José P. Román, Gonzalo González de Buitrago
-
Publication number: 20130079389Abstract: The invention relates to methods and compositions for the treatment/and or prevention of eye conditions related to high levels of expression and/or activity of the vanilloid-1 receptor (TRPV).Type: ApplicationFiled: May 27, 2011Publication date: March 28, 2013Applicant: SYLENTIS S.A.U.Inventors: Marta Lopez-Fraga, Ana Isabel Jimenez, Tamara Martinez Valcarel
-
Patent number: 8389490Abstract: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention.Type: GrantFiled: September 2, 2010Date of Patent: March 5, 2013Assignee: Sylentis S.A.U.Inventors: Ana I. Jiménez, Ángela Sesto, Irene Gascón, José P. Román, Gonzalo González de Buitrago
-
Patent number: 8354385Abstract: The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.Type: GrantFiled: October 20, 2006Date of Patent: January 15, 2013Assignee: Sylentis S.A.U.Inventors: Maria Del Carmen Acosta Boj, Juana Gallar Martinez, Angela Sesto Yague, Carlos Belmonte Martinez, Ana Isabel Jimenez Anton, Maria Concepcion Jimenez Gomez
-
Patent number: 8258110Abstract: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention.Type: GrantFiled: July 9, 2008Date of Patent: September 4, 2012Assignee: Sylentis S.A.U.Inventors: Ana I. Jiménez, Ángela Sesto, Irene Gascón, José P. Román, Gonzalo González de Buitrago
-
Patent number: 8252759Abstract: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention.Type: GrantFiled: July 9, 2008Date of Patent: August 28, 2012Assignee: Sylentis S.A.U.Inventors: Ana I. Jiménez, Ángela Sesto, Irene Gascón, José P. Román, Gonzalo González de Buitrago
-
Patent number: 8252758Abstract: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention.Type: GrantFiled: July 9, 2008Date of Patent: August 28, 2012Assignee: Sylentis S.A.U.Inventors: Ana I. Jiménez, Ángela Sesto, Irene Gascón, José P. Román, Gonzalo González de Buitrago
-
Patent number: 8247387Abstract: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention.Type: GrantFiled: July 9, 2008Date of Patent: August 21, 2012Assignee: Sylentis S.A.U.Inventors: Ana I. Jiménez, Ángela Sesto, Irene Gascón, José P. Román, Gonzalo González de Buitrago
-
Patent number: 8198250Abstract: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention.Type: GrantFiled: July 9, 2008Date of Patent: June 12, 2012Assignee: Sylentis S.A.U.Inventors: Ana I. Jiménez, Ángela Sesto, Irene Gascón, José P. Román, Gonzalo González de Buitrago
-
Publication number: 20120142765Abstract: The invention relates to novel oligomer analogues and their use in oligonucleotide-based therapies. More specifically, the invention concerns oligonucleotides carrying lipid molecules and their use as potential inhibitors of gene expression.Type: ApplicationFiled: June 22, 2010Publication date: June 7, 2012Applicant: Sylentis S.A.U.Inventors: Ana Isabel Jimenez, Gema Panizo, Tamara Martinez, Anna Avino, Clara Caminal, Ramon Eritja, Santiago Grijalvo
-
Patent number: 8188057Abstract: The invention relates to siNA compositions and methods for the treatment of eye conditions wherein the siNA compound capable of inhibiting the expression of 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD1).Type: GrantFiled: October 25, 2006Date of Patent: May 29, 2012Assignee: Sylentis S.A.U.Inventors: Ana Isabel Jiménez Anton, Ángela Seso Yague, María Concepción Jiménez Gomez
-
Publication number: 20110313016Abstract: Methods and compositions for the treatment of intestinal disorders, such as IBD and Crohn's disease, are disclosed. Preferred compositions include siNA. Also disclosed is a method of specifically targeting siNA to treat intestinal disorders by intrarectal administration of siNA compounds.Type: ApplicationFiled: March 14, 2006Publication date: December 22, 2011Applicant: Sylentis S.A.U.Inventors: Ana I. Jiménez, Irene Gascön, Maria Concepción Jiménez, José P. Román, Angela Sesto
-
Patent number: 8067577Abstract: Methods and compositions for the treatment of intestinal disorders, such as IBD and Crohn's disease, are disclosed. Preferred compositions include siNA. Also disclosed is a method of specifically targeting siNA to treat intestinal disorders by intrarectal administration of siNA compounds.Type: GrantFiled: August 30, 2010Date of Patent: November 29, 2011Assignee: Sylentis S.A.U.Inventors: Ana I. Jiménez, Irene Gascón, Maria Concepción Jiménez, José P. Román, Angela Sesto
-
Patent number: 8030284Abstract: Sequences and protocols for treatment of eye conditions by use of RNA interference are disclosed. Target genes are selected from those responsible for aqueous flow or aqueous outflow, while particularly preferred conditions to be treated include glaucoma and uveitis.Type: GrantFiled: August 23, 2005Date of Patent: October 4, 2011Assignee: Sylentis S.A.U.Inventors: Ana I. Jiménez, Ángela Sesto, José P. Roman, Irene Gascón, Gonzalo González de Buitrago
-
MODULATION OF 11 BETA-HYDROXYSTERIOD DEHYDROGENASE 1 EXPRESSION FOR THE TREATMENT OF OCULAR DISEASES
Publication number: 20110160277Abstract: The invention relates to siNA compositions and methods for the treatment of eye conditions wherein the siNA compound capable of inhibiting the expression of 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD1).Type: ApplicationFiled: October 25, 2006Publication date: June 30, 2011Applicant: SYLENTIS S.A.U.Inventors: Ana Isabel Jiménez Anton, Ángela Sesto Yague, María Concepción Jimenez Gomez -
Patent number: 7902169Abstract: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention.Type: GrantFiled: September 21, 2009Date of Patent: March 8, 2011Assignee: Sylentis S.A.U.Inventors: Ana I. Jiménez, Ángela Sesto, Irene Gascón, José P. Román, Gonzalo González de Buitrago